All Interventions

    Comprehensive Blood Panel

    Diagnostics
    Blood Testing

    Advanced blood testing beyond standard panels to optimize biomarkers and detect early dysfunction.

    Evidence Summary

    9
    / 10Score
    Strong
    Strong RCT Evidence

    Foundation of precision health. Beyond standard testing identifies subclinical dysfunction. Optimal ranges differ from conventional "normal" ranges. UPDATE (November 4, 2026): A landmark New England Journal of Medicine 2024 analysis of the Women's Health Study (Ridker et al.; 27,939 initially healthy U.S. women followed for 30 years, 3,662 first major cardiovascular events) showed that a single baseline panel measuring high-sensitivity CRP (inflammation), LDL cholesterol, and lipoprotein(a) each independently predicted cardiovascular risk three decades later. Comparing the top with the bottom quintile, covariable-adjusted hazard ratios for a first major cardiovascular event (myocardial infarction, coronary revascularization, stroke, or cardiovascular death) were 1.70 (95% CI 1.52-1.90) for high-sensitivity CRP, 1.36 (95% CI 1.23-1.52) for LDL cholesterol, and 1.33 (95% CI 1.21-1.47) for lipoprotein(a); the widest separation in risk came from models combining all three markers. This reinforces the rationale for a comprehensive panel - measuring inflammation and lipoprotein(a) alongside standard cholesterol (and increasingly apolipoprotein B) rather than lipids alone - and for extending primary-prevention risk assessment beyond the usual 10-year horizon. These are observational associations in women; biomarkers inform risk stratification, not diagnosis, and targets and treatment decisions should be individualized with a qualified clinician. UPDATE (August 9, 2026): Nature Aging 2026 (Yu, Chen, Feng, Li et al.) reports the most credible ultra-early MASLD stratification tool published to date: a five-protein plasma panel - FUOM, ACY1, KRT18, CDHR2 and GGT1 - identified and validated across more than 50,000 participants from Southern UK, Northern UK, EPIC-Norfolk and a Southern China inception cohort. Performance was 5-year AUC 0.838 and 16.6-year AUC 0.756, sustained longitudinally in EPIC-Norfolk (AUC 0.710) and reaching 0.912 in the Chinese cohort; integrating routine clinical data raised these to 0.904 and 0.822. Note that GGT1 is already on most comprehensive panels, so part of this signal is accessible today. Important limits: this is an observational prediction model, no trial has shown that acting on the signature changes hepatic outcomes, and the assay is not clinically standardised or reimbursed.

    Evidence Scale

    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    AnecdotalStrong RCT

    Mechanism of Action

    Measures metabolic, hormonal, inflammatory, and nutritional markers. Enables data-driven optimization and early disease detection.

    Who Is This For?

    Universal application. Foundation for any optimization program. Earlier detection than symptom-based care.

    Protocol & Dosing

    Dose

    Comprehensive panel including: metabolic, lipid, hormonal, inflammatory, nutritional, and organ function markers.

    Frequency

    Baseline + quarterly to annually

    Duration

    Periodic monitoring

    Protocol Summary

    Fasting blood draw. 50-100+ biomarkers depending on panel. Include hormones, lipids, metabolic, inflammatory, and nutrient markers. For cardiovascular risk, measure high-sensitivity CRP, lipoprotein(a) (largely genetic, typically measured once), and apolipoprotein B alongside a standard lipid panel, and interpret trends over time rather than single values.

    Latest Evidence

    2024: one blood panel predicted cardiovascular risk 30 years out

    In the New England Journal of Medicine (2024), a 30-year analysis of the Women's Health Study followed 27,939 initially healthy U.S. women and recorded 3,662 first major cardiovascular events. A single baseline measurement of high-sensitivity CRP (inflammation), LDL cholesterol, and lipoprotein(a) each independently predicted risk three decades later. Comparing the top with the bottom quintile, adjusted hazard ratios for a first major cardiovascular event were 1.70 for high-sensitivity CRP, 1.36 for LDL cholesterol, and 1.33 for lipoprotein(a) - and the sharpest risk stratification came from measuring all three together. It is a concrete argument for a comprehensive panel that includes inflammation and lipoprotein(a), not lipids alone, and for looking beyond the usual 10-year risk window.

    These are observational associations in women; a blood panel informs risk stratification, not a diagnosis, and no single measurement captures individual risk on its own. Lipoprotein(a) is largely genetic and typically measured once. Optimal ranges and treatment decisions should be individualized with a qualified clinician. Educational information, not medical advice.

    Women's Health Study · 27,939 women · 30-yr follow-up · NEJM 2024

    Three biomarkers, each an independent 30-year risk signal

    Covariable-adjusted hazard ratios for a first major cardiovascular event (myocardial infarction, coronary revascularization, stroke, or cardiovascular death), comparing the top with the bottom quintile of each baseline biomarker; each marker contributed independently, and combining all three gave the greatest spread in risk. Source: Ridker PM, Moorthy MV, Cook NR, Rifai N, Lee I-M, Buring JE. Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women. N Engl J Med. 2024;391(22):2087-2097.

    Key references: Ridker PM, Moorthy MV, Cook NR, et al. - Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women, N Engl J Med (2024) · Sehayek, Sniderman et al. - ApoB, LDL-C and non-HDL-C as risk markers, J Clin Lipidol (2025) · Epstein et al. - ApoB outperforms LDL particle number, UK Biobank, Eur J Prev Cardiol (2025)

    Interactions & Precautions

    Contraindications

    • None

    Potential Risks

    • •Cost
    • •Over-testing anxiety
    • •Misinterpretation without guidance

    Potential Side Effects

    Blood draw discomfort
    Potential anxiety from results

    Practitioner Notes

    Clinical annotations from Dr. Goel

    Optimal ranges differ from conventional. Track trends over time. Annual comprehensive with quarterly targeted testing. Interpret in context of symptoms and goals. Updated August 9, 2026: For metabolic-health patients, the 2026 five-protein MASLD signature (FUOM, ACY1, KRT18, CDHR2, GGT1) is worth knowing about because the prediction horizon is 16 years — well upstream of imaging or elastography. Practically, only GGT1 is routinely available now; treat the full panel as an emerging research tool rather than something to order. Present it as risk stratification, not diagnosis, and be explicit that no intervention trial has yet been anchored to this signature. Updated November 4, 2026: The 2024 Women's Health Study 30-year data (Ridker, NEJM) are a practical argument for a comprehensive panel - high-sensitivity CRP, LDL-C and lipoprotein(a) each carried independent long-range risk, and the sharpest stratification came from measuring all three together. Order hs-CRP and a one-time Lp(a) alongside an apoB-inclusive lipid panel for primary-prevention patients, and frame results as decades-long risk stratification, not a diagnosis. Educational information, not medical advice.
    SG

    Dr. Sanjeev Goel

    Chief Medical Officer, Peak Human

    Cost & Access

    Cost Range

    $$

    Accessibility

    Labs and specialty clinics

    Availability varies by location

    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation